is a global biopharmaceutical company focusing on oncology and auto-immune diseases with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide. Founded in 2010 and headquartered in Shanghai, they have built three global R&D facilities in Shanghai, Taipei and California collaborating with each other to ensure the highly productive and cost-efficient R&D processes. Discovering new ways to improve and extend patients’ lives by driving access to high-quality biologic medicines worldwide, we are committed to biosimilars, innovative monoclonal antibody (mAb) products and immuno-oncology combination therapies with proprietary anti-PD-1/PD-L1 mAbs as backbones on an integrated platform covering the entire product lifecycle from R&D, commercial-scale production to commercialisation. On September 25, 2019, we were successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited under the stock code 2696.HK.


Biosimilar:Our product pipeline covers several advanced mAb biosimilar candidates with near-term commercial visibility. 汉利康® (rituximab injection), our first product, has been granted NDA approval by the NMPA as the first biosimilar in China in February, 2019.

Bio-Innovative:Leveraging the development experience of biosimilar, we are developing comprehensive bio-innovative pipeline and driving worldwide clinical studies of novel products for the long-term growth.

Combo Therapy:We have versatile in-house combination therapy portfolio with a focus on anti-PD-1/PD-L1 mAb to capture future immuno-oncology opportunities with the aim of providing affordable and effective therapies. 

Boundless Bio